Crown Bioscience Hires Two Industry Veterans for Expansion in Asia-Pacific Region
October 20, 2015
(SANTA CLARA, CALIF., OCT. 20, 2015) — CROWN BIOSCIENCE, A GLOBAL DRUG DISCOVERY AND DEVELOPMENT SERVICES COMPANY PROVIDING TRANSLATIONAL PLATFORMS TO ADVANCE ONCOLOGY AND METABOLIC DISEASE RESEARCH, HAS ANNOUNCED THE APPOINTMENT OF TWO RESPECTED INDUSTRY VETERANS TO ITS BUSINESS DEVELOPMENT TEAM TO SUPPORT ITS EXPANSION IN THE ASIA-PACIFIC REGION.
Tetsuya Totsuka, Ph.D., has been named manager of business development for Japan. Before joining Crown Bioscience, Totsuka was director and COO of business development for a Tokyo-based biotech firm and director of the original developer of disparity mutagenesis technology for the improvement and breeding of useful organisms, including microorganisms, cultured cells, plants and animals. Totsuka also held key positions with several leading pharmaceutical companies. He earned his bachelor’s degree in biochemistry from the University of Tokyo and his Ph.D. from Tokyo Medical and Dental University.
Mayet Pantastico will be the director of business development for Australia, Singapore, New Zealand and Korea. With more than 14 years of experience in sales and business development in the pharmaceutical industry, she was most recently sales and marketing manager in the Asia-Pacific region for a preclinical CRO focused on oncology models and GLP toxicology studies. She was also business development manager for a preclinical CRO focused on translational models, and she had sales and management roles with several other leading life sciences companies.
“Both Mayet and Tetsuya are highly respected professionals with experience in the Asia-Pacific region,” said Laurie Heilmann, senior vice president of global strategy, marketing and business development at Crown Bioscience. “We have seen significant growth in this region, and we are expanding our presence there to meet the demand for our cutting-edge translational platforms and cost-effective drug development solutions for pharmaceutical companies in the region.”
For more information about how Crown Bioscience preclinical models help move new compounds forward, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visitwww.crownbio.com.